Background: Acute coronary syndromes account for half of all deaths secondary to cardiovascular disease and represent a significant economic burden in the United States. Therefore, assessing hospitalization costs relative to Medicare reimbursement for these patients is important in understanding the impact of these patients on hospitals. We hypothesized that hospitalization costs for acute myocardial infarction patients treated with percutaneous coronary intervention (PCI) were higher than their associated Medicare payments. Methods: Using the Nationwide Inpatient Sample, we evaluated hospitalization costs for patients treated with PCI from 2001 through 2009 by multiplying hospital charges by the group average cost-to-charge ratio for each patient's hospitalization. Primary end points examined were total hospital costs and trends over time, which were correlated with clinical outcomes and insurance payments. Conclusions: Hospitalization costs for patients treated with PCI have been stabilizing over the last few years; however, there still remains a significant disparity between Medicare reimbursements and hospitalization costs, which has potential implications on patient outcomes, quality of care, and hospital sustainability.
Introduction
Although cardiovascular disease mortality rates have slowly declined in the United States, they still remain the leading cause of death in both men and women. 1 Acute coronary syndromes, which include unstable angina, non-ST-segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI), account for half of all deaths due to cardiovascular disease. 2 Given the large number of admissions for acute coronary syndromes, it is important to assess the economic impact these patients have on hospitals. Furthermore, it is essential to understand hospitalization costs, because Medicare payments may not be adequately reimbursing costs of treatment. Therefore, in
States. Using the NIS for years 2001 through 2009, patients who underwent PCI were identified using the International Classification of Diseases, 9th Revision (ICD-9) procedure codes 0066, 3603, 3604, 3606, 3607, 3609. Of these patients, we selected those with a primary ICD-9 diagnosis code of NSTEMI (41070, 41071) 
Cost Data
We determined an association between the following variables and total costs in the 2009 sample: age, gender, discharge status (home/short-term facility, long-term facility, and in-hospital death), primary payer (Medicare, Medicaid, private insurance, self-pay, no charge, other), race, patient household income quartile (based on the patients' home zip codes), Charlson Comorbidity Index (CCI), procedure type (drug-eluting stent, bare-metal stent, angioplasty without stenting), intensive care unit (ICU) stay, hospital region (Northeast, Midwest, South, West), hospital location/teaching status (rural, urban nonteaching, urban teaching), and hospital bed size (small, medium, large). Mechanical ventilation (ICD-9 procedure codes 9670-9672), was used as a surrogate for ICU stay. Hospitalization costs were determined by taking the total hospitalization charges and multiplying them by the group average costto-charge ratio (CCR) for each patient's hospitalization. Hospitalization charges and CCR were provided by the NIS database.
The NIS database provides data on the total hospitalization charges and the CCR. These charges represent the amount that hospitals billed for their services, but do not reflect how much the services actually cost or the specific amounts that hospitals received in payment. The CCR allows one to see how hospital charges translate into actual costs. 4 The CCRs provided are based on all-payer inpatient cost, which was obtained from accounting reports collected by the Centers for Medicare & Medicaid Services.
We examined trends in inflation-adjusted hospitalization costs of PCI for AMI from 2001 through 2009. To account for inflation we used the general consumer price index calculator (available at http://data.bls.gov/cgibin/cpicalc.pl) and converted all costs and charges to their dollar value in 2009.
Comparison With Medicare Reimbursements
For patients whose hospitalization was paid for by Medicare in 2009, we compared the cost of hospitalization to mean Medicare payments for the Medicare Severity-Diagnosis Related Groups (MS-DRG) of the hospitalization. Diagnosis Related Groups (DRGs) included in our study were 246 (percutaneous cardiovascular procedure with drug-eluting stent with major complication or comorbidity or 4+ vessels/ stents), 247 (percutaneous cardiovascular procedure with drug-eluting stent without major complication or comorbidity), 248 (percutaneous cardiovascular procedure with non-drug-eluting stent with major complication or comorbidity or 4+ vessels/stents), 249 (percutaneous cardiovascular procedure with non-drug-eluting stent without major complication or comorbidity), 250 (percutaneous cardiovascular procedure without coronary artery stent with major complication or comorbidity), 251 (percutaneous cardiovascular procedure without coronary artery stent without major complication or comorbidity). These DRGs were applied only to patients who suffered from an AMI requiring PCI. Medicare payments are public information (http://www.cms.hhs.gov).
Statistical Analysis
We used the nonparametric Wilcoxon rank sum test to determine statistical significance, defined as a P value <0.05. We also present medians and interquartile ranges. Multivariate analysis to determine predictors of cost for patients in 2009 was performed using a standard least squares model. Variables included in the model were age, gender, race, discharge status, procedure type, NSTEMI vs STEMI, insurance status, zip income quartile, CCI, hospital region, hospital location/teaching status, hospital bed size, and ICU stay. All potential predictors of cost were forced into the model. Given that the study involved publically available, coded information that could not be linked to specific individuals directly or indirectly, this study was felt to be exempt from institutional review board approval. All statistical analysis was performed using the SAS-based statistical software JMP (www.jmp.com; SAS Institute Inc., Carey, NC).
Results

Patient Data
Cost data from 2009 were available for a total of 265 531 patients. Of these, 137 863 patients suffered a STEMI (51.9%) and 127 668 suffered a NSTEMI (48.1%). In terms of age, 143 654 (54.1%) were younger than 65 years, and 121 876 (45.9%) were ≥65 years. In regard to discharge status, 247 194 (93.1%) patients were discharged to home/ short-term facility, 13 183 (5.0%) patients were discharged to long-term facilities, and 5055 (1.9%) patients suffered inhospital mortality. There were 11 192 (4.2%) patients who required mechanical ventilation.
Hospital Data
Of the 265 531 hospitalizations for AMI, the majority of these were located in the Southern United States, in urban settings, and in large-bed-size hospitals. Specific details of hospital data can be seen in Table 1 .
Hospitalization Costs in 2009
Cost data are also summarized in Table 1 . The median cost for all patients hospitalized in 2009 was $19 349 (interquartile range [IQR] = $14 660-$26 282). There was a significant difference in the median costs for patients <65 years old compared to ≥65 years old (P < 0.0001). Patients discharged to home or short-term facilities had significantly lower median costs when compared to those patients discharged to long-term facilities ($18 949 vs $30 007, P < 0.0001). Costs varied significantly by primary payer, with Medicare patients having the highest median costs compared to those with no charge or self-pay. Patients receiving drugeluting stents had significantly higher costs than patients 14 Clin. Cardiol. 38, 1, 13-19 (2015) receiving bare-metal stents and those receiving angioplasty without stenting. Hospital location, region, and bed size also showed differences in cost, with the Western United States region, rural locations, and small-bed-size hospitals having significantly higher costs (P < 0.0001).
Predictors of Cost With Multivariate Analysis
When performing our multivariate analysis, we found that age, female gender, discharge to long-term facility, insurance status (true for public insurance vs private insurance, and private insurance vs self-pay), race, income quartile, procedure type, hospital region, hospital location/ teaching status, hospital bed size, and ICU stay were independent predictors of increased costs (P < 0.0001).
Charlson Comorbidity Index was also an independent predictor of increased costs (P = 0.0005) Table 2 . Although not addressed in this study, other studies demonstrate that rehospitalizations during the 1-year followup after PCI also pose significant cost as well. 6 This could potentially add to the cost-payment discrepancies described in this study. Several studies have described the overall cost fluctuations to the Medicare program over the study period 7, 8 ; however, to the best of our knowledge, this present study represents the first examination of index hospitalization costs and payments for PCI in acute coronary syndromes. Similar cost studies analyzing endovascular treatments in patients with acute ischemic stroke and unruptured cerebral aneurysms have also shown that Medicare payments are not sufficiently meeting hospitalization costs, 9,10 a predicament that needs further attention.
Cost Trends Over Time
In the era of dramatic changes to the healthcare economic landscape, such as the Balanced Budget Act (BBA) of 1997, and more recently the Affordable Care Act (ACA) of 2010, Medicare payment implications on hospital quality of care and patient outcomes has become a hot topic of discussion. Authors Shen and Wu have shown that hospitals facing large payment cuts experienced slower improvement in patient mortality rates in the post-BBA period with relation to AMI patient outcomes, relative to those facing small payment cuts, and that Medicare price cuts lead to reduced staffing and operating expenses, which they tied to increases in patient mortality rates. and that hospitals with worse financial condition ultimately had to curtail investments in important areas, such as infrastructure, nursing staff, patient support and safety services, and quality-enhancing activities. 13 -15 White and Wu performed a unique analysis looking at the longterm effect of BBA, studying the period of 1996 through 2009 and excluding small rural hospitals, allowing time to appropriately adjust to the Medicare payment changes. They concluded that hospitals' total revenues will drop under the ACA by more than expected based on just Medicare price changes, and that a significant percentage of lost revenues will be offset by reduced operating expenses, mainly via savings on personnel, but also nonpersonnel costs, along with delaying or forgoing capital improvements. 16 Volpp et al have previously shown that the BBA did not have a significant impact on 30-day mortality in AMI, but suggested that in the long run, reductions in margins could potentially translate into reductions in capital investments, infrastructure improvements, and quality-improvement initiatives that could reduce the rate of improvement in care. 17 These are important points to consider, as the BBA and ACA both lower hospital spending primarily by reducing DRG payment increases; however, the rate of payment reduction as part of the ACA is actually larger than the BBA, with the ACA reducing DRG payment by an estimated 1.1% per year indefinitely vs the BBA, which reduced Medicare inpatient payment by 5% between 1998 and 2000. 18, 19 We also demonstrated that insurance status was significantly associated with hospitalization costs when controlling for age, gender, comorbidities, and outcomes. Patients who had Medicare or Medicaid as the primary payer had significantly higher hospitalization costs than patients with private insurance, and privately insured patients had a higher cost than those who were uninsured. The significance of higher hospitalization costs for patients on public insurance is unclear. The association of higher cost with race may be related to other unmeasured comorbidities, whereas the association with income status remains unclear and requires further study and elucidation. This may be due to a number of factors including differences in resource utilization during the hospitalization based off of insurance status and income. We cannot exclude the interaction of other factors not measured in this database. Differences in costs and charges by insurance status have been demonstrated in previous studies. 20 Although not the major focus of this current study, literature regarding performing transradial percutaneous coronary intervention (TRPCI) over transfemoral percutaneous coronary intervention (TFPCI) has been growing in interest. 21 A recent meta-analysis of randomized controlled trials comparing TRPCI vs TFPCI in STEMI patients showed that TRPCI had a statistically significant 48% reduced risk of major bleeding, 42% reduced risk of mortality, and a 33% reduced risk of major adverse cardiac event. This study also showed a significantly shorter hospital stay in the transradial group, but also higher frequency of access site crossover and a non-statistically significant longer time to reperfusion. 22 The implications of that meta-analysis can be considered in light of other recent studies that assess the hospitalization costs of TRPCI vs TFPCI, and have found that TRPCI was associated with lower average total costs of care, primarily driven by reduced length of stay and bleeding complications. 23 Recent work has estimated that TRPCI results in approximately $730 to $800 savings per PCI procedure, which when compared to TFPCI could amount to significant reductions in annual hospitalizations costs. 24, 25 Although the transfemoral approach remains the most commonly used technique, further studies regarding transradial PCI could potentially help with the problem of determining ways of reducing hospitalization costs.
Coding errors are a potential limitation of this study, as they are with any study using a large administrative database. However, the very large numbers in this database should minimize that limitation. Another potential limitation is our use of CCRs in determining hospitalization costs. A hospital CCR is a reflection of a hospital's annual total costs divided by the annual total charges. The major components of hospital costs that can be included in a hospital CCR include the cost of devices and pharmaceuticals, employee costs (nurses, pharmacists, physicians, technologists), and malpractice insurance. Other ancillary costs that are components of CCR include building costs, maintenance costs, outpatient services, hospital investments, and loan repayments. Thus, some components of the cost of hospitalizations are not directly related to patient care but rather to institutional expenses, such as investments and loan repayments, that are distributed among the patient population.
In our study, we used average nationwide reimbursement rates for the 6 procedure-related DRG codes in calculating the disparities between costs and reimbursement. Hospitals receive different payments for DRGs depending on their location, teaching status, and case mix. We were able to show significant differences in costs based on hospital region, location/teaching status, and bed size; however, we could not obtain data on DRG reimbursement rates for specific hospitals, as these data are not available. Nonetheless, given the differences between hospitalization costs of Medicare patients in this study and the amount that Medicare reimbursed, on average, it is reasonable to assume that failure to reimburse for costs based on these CCRs caused hospitals to lose a considerable amount of money that could be invested into patient care. Furthermore, the costs and reimbursements addressed here refer specifically to index hospitalizations, and do not include out-of-hospital or follow-up costs for patients undergoing PCI, which can potentially contribute significantly to the overall costs of care. The costs of PCI also refer to all PCI procedures and do not differentiate between which access site was used. Cost trends discussed in this study were not compared with payment trends over the entire study period, as the most recent year included was felt sufficient to represent a clear disparity. Finally, the mean Medicare payments were reported rather than individual payments. This may affect the accuracy of the reported payments; however, the means should be a good reflection of general trends given the large sample size studied. been stabilizing over the recent studied years, but more importantly, Medicare payments clearly have not been adequately reimbursing these hospitalizations. Therefore, for hospitals to maintain economic stability in caring for these patients, strident efforts should be made to both significantly reduce hospitalization costs and encourage Medicare to adequately reimburse hospitals for the services that they provide. Interesting nonclinical predictors of cost are noted and deserve further study and analysis. Furthermore, past experiences with the BBA of 1997 may help predict long-term implications of the ACA of 2010 on hospital outcomes, quality of care, and sustainability. Further analysis of the impact of the ACA on hospitals will be important to conduct, especially with common conditions that require hospitalizations such as AMI.
